OBJECTIVES Ursodeoxycholic acid (UDCA) is used for primary biliary cirrhosis (PBC), but
the beneficial effects remain controversial. METHODS We performed an updated systematic …

Background & Aims Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a
semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural …

OBJECTIVES The effect of ursodeoxycholic acid (UDCA) treatment on survival and liver
histological progression of primary biliary cirrhosis (PBC) remains uncertain. The aim of this …

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the most
frequent chronic cholestatic liver diseases and serve as model diseases to discuss the …

Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary
cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports …

Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential …

Background & Aims The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …

Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II
double‐blind, placebo‐controlled study, we tested the safety and efficacy of cilofexor …

Aliment Pharmacol Ther 2011; 34: 1185–1192 Summary Background Ursodeoxycholic acid
(UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of …

Background Bile acid diarrhoea is a common cause of chronic diarrhoea, occurring as a
primary condition or secondary to ileal disease or resection. Many patients have reduced …